2026 Jefferies Healthcare Services and Technology Conference
Logotype for Addus HomeCare Corporation

Addus HomeCare (ADUS) 2026 Jefferies Healthcare Services and Technology Conference summary

Event summary combining transcript, slides, and related documents.

Logotype for Addus HomeCare Corporation

2026 Jefferies Healthcare Services and Technology Conference summary

15 Sep, 2026

Major acquisition and integration plans

  • Announced acquisition of a large personal care division, concentrated in Texas, Illinois, California, and Arizona, for $275 million, expected to close in Q1 2027 pending regulatory approval.

  • Integration will mirror a previous Gentiva transaction, with a favorable timeframe and experienced team; system conversions and operational synergies are anticipated.

  • Revenue run rate for the acquired assets is $280 million, with gross margins expected in the upper 20% range and EBITDA synergies to be realized over 12–18 months.

  • EMR conversion to Homecare Homebase is scheduled for late 2027 or early 2028, with current systems maintained until then.

  • Positive feedback from payers on the acquisition, with opportunities for value-based contracts and network consolidation.

Operational performance and technology initiatives

  • Same-store performance accelerated in Q2, driven by improved fill rates (84–85%) and targeted growth of 2–2.5% in hours year-over-year.

  • Rate increases in Illinois, Texas, and New Mexico have supported growth, with expectations to remain at the high end of the 3–5% target range.

  • Caregiver app in Illinois enables real-time scheduling adjustments, boosting utilization and fill rates; rollout to other states is ongoing.

  • Labor environment is stable and competitive due to state rate support and flexible scheduling.

Home health and M&A strategy

  • Home health admissions grew 9.8% in Q2, attributed to leadership changes and process standardization; focus remains on profitable growth.

  • Appetite for home health acquisitions remains, with personal care as the primary M&A focus; more large opportunities expected in the next 12–18 months.

  • Ideal acquisition targets are at scale in new markets, with strong compliance and clinical processes; IT system compatibility is not a barrier.

Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.
All investor relations material. One API.
Learn more